ARGX Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Developments:
Argenx (ARGX) has seen positive developments recently, with analyst upgrades and promising clinical trial data. Bernstein upgraded ARGX to Outperform with a price target of EUR 755, driven by increased sales forecasts for Vyvgart, now expected to reach $11B by 2030. Evercore ISI maintained a Buy rating with a $713 target, reflecting confidence in the stock's growth potential. Clinical trial data presented at the American Academy of Neurology meeting highlighted sustained efficacy and safety of Vyvgart, reinforcing its market position.
Technical Analysis:
The stock's technical indicators show mixed signals but lean towards bullish momentum:
- RSI: At 56.13 (RSI_6), 49.93 (RSI_12), and 49.13 (RSI_14), the stock is not overbought, indicating room for upside.
- MACD: The MACD line (-6.79) is below the signal line, suggesting bearish momentum, but the MACD Histogram (2.76) indicates weakening bearish pressure.
- Stochastic Oscillator: %K (65.83) and %D (63.07) are in the middle range, not triggering a strong buy or sell signal.
- Fibonacci Levels: The stock is near the first resistance level (621.20), with a pivot point at 596.74.
- Bollinger Bands: The price is near the middle band, suggesting potential volatility.
Price Action and Volume:
The stock closed at 615.02, up 0.32% from the previous day, with average volume of 250,919. The price is approaching the upper Bollinger Band (662.94), indicating possible upside.
Conclusion:
Given the positive news and mixed but improving technicals, ARGX is expected to rise. The target price for the next trading week is $640.
ARGX Similar Chart Price Prediction
The price of ARGX is predicted to go up 7.99%, based on the high correlation periods with VNET. The similarity of these two price pattern on the periods is 94.78%.
ARGX
VNET
Up: 7.99%Similarity: 94.78%
ARGX Revenue Forecast
ARGX EPS Forecast
ARGX FAQs
What is ARGX revenue forecast for next quarter？
What is ARGX eps forecast for next quarter？
ARGX VS S&P500
Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis but in testing in multiple additional indications.
Vyvgart's approval in myasthenia gravis made it the first-to-market FcRn-targeting drug, putting Argenx in a strong position to entrench itself in the market before competitors arrive.
With exclusive access to Halozyme's subcutaneous drug delivery technology, Argenx can improve the convenience of Vyvgart and potentially differentiate its drug from future competition.
ARGX Analyst's Forecast
Yatin Suneja
Guggenheim
Strong Buy
2025-03-10
Price Target
$775 → $1,100
Upside
+92.64%
Guggenheim raised the firm's price target on Argenx to $1,100 from $775 and keeps a Buy rating on the shares. Argenx has set "clear and bold goals with their 2030 agenda," which include reaching 50,000 patients on treatment in 10 labeled indications and bringing five new molecules to Phase 3 by 2030, notes the analyst. The firm's analysis suggests the company could "nearly double its market capitalization" within five years, the analyst tells investors.
Joel Beatty
Baird
Hold
2025-03-04
Price Target
$650 → $680
Upside
+8.54%
Joon Lee
Truist Securities
Strong Buy
2025-01-14
Price Target
$660 → $700
Upside
+5.14%
